title: Efficacy of Tenofovir 1% Vaginal Gel in Reducing the Risk of HIV-1 and HSV-2 Infection.
abstract: Human Immunodeficiency Virus (HIV) is a retrovirus that can result in rare opportunistic infections occurring in humans. The onset of these infections is known as Acquired Immune Deficiency Syndrome (AIDS). Sexual transmission is responsible for the majority of infections 1, resulting in transmission of HIV due to infected semen or vaginal and cervical secretions containing infected lymphocytes. HIV microbicides are formulations of chemical or biological agents that can be applied to the vagina or rectum with the intention of reducing the acquisition of HIV. Tenofovir is an NRTI that is phosphorylated by adenylate kinase to tenofovir diphosphate, which in turn competes with deoxyadeosine 5'-triphosphate for incorporation into newly synthesized HIV DNA. Once incorporated, tenofovir diphosphate results in chain termination, thus inhibiting viral replication. Tenofovir has been formulated into a range of vaginal formulations, such as rings, tablets gels and films. It has been shown to safe and effective in numerous animal models, while demonstrating safety and acceptability in numerous human trials. The most encouraging results came from the CAPRISA 004 clinical trial which demonstrated that a 1% Tenofovir vaginal gel reduced HIV infection by approximately 39%.
authors.affiliation: Department of Pharmacy, Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton, UK.
authors.forename: Christopher
authors.initials: C
authors.lastname: McConville
authors.affiliation: School of Pharmacy, Medical Biology Centre, Queen's University of Belfast, Belfast, Northern Ireland, UK.
authors.forename: Peter
authors.initials: P
authors.lastname: Boyd
authors.affiliation: Materials Research Institute, Athlone Institute of Technology, Athlone, Westmeath, Ireland.
authors.forename: Ian
authors.initials: I
authors.lastname: Major
keywords: HIV; HSV; microbicide; tenofovir; vaginal gel
references.citation: Contraception. 2013 Jul;88(1):58-66
references.pmid: 23177261
references.citation: AIDS. 2011 Jan 14;25(2):207-10
references.pmid: 21150556
references.citation: AIDS. 2006 Feb 28;20(4):543-51
references.pmid: 16470118
references.citation: Cell Host Microbe. 2011 Oct 20;10(4):379-89
references.pmid: 22018238
references.citation: Contraception. 2002 Nov;66(5):365-8
references.pmid: 12443968
references.citation: Annu Rev Biochem. 1991;60:577-630
references.pmid: 1883204
references.citation: Antimicrob Agents Chemother. 2001 Aug;45(8):2229-37
references.pmid: 11451679
references.citation: Science. 2010 Sep 3;329(5996):1168-74
references.pmid: 20643915
references.citation: Clin Infect Dis. 2003 Apr 15;36(8):1070-3
references.pmid: 12684922
references.citation: N Engl J Med. 2012 Aug 2;367(5):423-34
references.pmid: 22784038
references.citation: J Infect Dis. 2005 Dec 1;192(11):1921-30
references.pmid: 16267763
references.citation: Nat Rev Drug Discov. 2002 Dec;1(12):977-85
references.pmid: 12461519
references.citation: J Infect Dis. 2011 Jun 15;203(12):1791-801
references.pmid: 21606537
references.citation: Microbiol Rev. 1995 Mar;59(1):63-93
references.pmid: 7708013
references.citation: N Engl J Med. 2012 Aug 2;367(5):411-22
references.pmid: 22784040
references.citation: Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16145-50
references.pmid: 24043812
references.citation: AIDS Res Hum Retroviruses. 1998 Apr;14 Suppl 1:S17-21
references.pmid: 9581879
references.citation: Science. 1995 Nov 17;270(5239):1197-9
references.pmid: 7502044
references.citation: Antimicrob Agents Chemother. 2000 Jul;44(7):1954-60
references.pmid: 10858360
references.citation: Collegian. 2012;19(1):23-32
references.pmid: 22482279
references.citation: Nat Rev Microbiol. 2003 Oct;1(1):25-34
references.pmid: 15040177
references.citation: J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):416-23
references.pmid: 19623693
references.citation: Nephrol Dial Transplant. 2005 Apr;20(4):743-6
references.pmid: 15741212
references.citation: Lancet. 2008 Aug 23;372(9639):646-55
references.pmid: 18722869
references.citation: Antimicrob Agents Chemother. 2004 Jan;48(1):337-9
references.pmid: 14693562
references.citation: Clin Infect Dis. 2003 Aug 1;37(3):e41-3
references.pmid: 12884188
references.citation: Clin Infect Dis. 2003 Dec 15;37(12):e174-6
references.pmid: 14689363
references.citation: J Virol. 2002 Feb;76(3):1004-14
references.pmid: 11773376
references.citation: Nature. 1986 Mar 27-Apr 2;320(6060):367-71
references.pmid: 3007995
references.citation: J Antimicrob Chemother. 2005 Aug;56(2):270-2
references.pmid: 15980096
references.citation: Lancet. 2012 Jun 30;379(9835):2439-2448
references.pmid: 22748591
references.citation: JAMA. 2004 Jul 14;292(2):191-201
references.pmid: 15249568
references.citation: J Virol. 2009 Oct;83(20):10358-65
references.pmid: 19656878
references.citation: J Virol. 2000 Oct;74(20):9771-5
references.pmid: 11000253
references.citation: Contraception. 2012 Jan;85(1):99-107
references.pmid: 22067809
references.citation: Nature. 1998 Jun 18;393(6686):648-59
references.pmid: 9641677
references.citation: PLoS One. 2010 Feb 19;5(2):e9310
references.pmid: 20174579
references.citation: AIDS Res Hum Retroviruses. 2002 Jul 20;18(11):747-55
references.pmid: 12167266
references.citation: Antimicrob Agents Chemother. 1998 Sep;42(9):2380-4
references.pmid: 9736567
references.citation: PLoS One. 2013;8(1):e55013
references.pmid: 23383037
references.citation: Lancet. 2011 Jul 16;378(9787):238-46
references.pmid: 21763936
references.citation: J Mol Biol. 1999 Jan 8;285(1):1-32
references.pmid: 9878383
references.citation: Virology. 1998 Nov 10;251(1):1-15
references.pmid: 9813197
references.citation: Science. 1997 Nov 21;278(5342):1447-50
references.pmid: 9367954
references.citation: J Pharm Sci. 2013 Jun;102(6):1859-1868
references.pmid: 23568749
references.citation: Clin Ther. 2002 Oct;24(10):1515-48
references.pmid: 12462284
references.citation: N Engl J Med. 2012 Aug 2;367(5):399-410
references.pmid: 22784037
references.citation: J Womens Health (Larchmt). 2008 Apr;17(3):383-92
references.pmid: 18328009
references.citation: Pharm Res. 2012 Jul;29(7):1897-907
references.pmid: 22392331
references.citation: AIDS. 2003 Apr 11;17(6):935-7
references.pmid: 12660548
references.citation: Antimicrob Agents Chemother. 2004 Jun;48(6):2091-6
references.pmid: 15155205
references.citation: Clin Infect Dis. 2010 Sep 1;51(5):496-505
references.pmid: 20673002
references.citation: J Infect Dis. 2005 Oct 15;192(8):1315-7
references.pmid: 16170746
references.citation: Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13878-83
references.pmid: 11717444
references.citation: Contraception. 1998 Oct;58(4):245-9
references.pmid: 9866007
references.citation: Lancet. 2007 Nov 17;370(9600):1698-705
references.pmid: 17997151
references.citation: BMC Infect Dis. 2005 Sep 30;5:79
references.pmid: 16194280
references.citation: Clin Infect Dis. 2009 Nov 15;49(10):1591-601
references.pmid: 19842973